Which has preferable earnings and valuation, ABVX or RVMD?

Revolution Medicines is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Revolution Medicines N/A N/A -$1.13B -$7.07 N/A

Is ABVX or RVMD more profitable?

Revolution Medicines' return on equity of -83.22% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Revolution Medicines N/A -83.22% -59.06%

Does the media favor ABVX or RVMD?

In the previous week, Revolution Medicines had 14 more articles in the media than Abivax. MarketBeat recorded 23 mentions for Revolution Medicines and 9 mentions for Abivax. Abivax's average media sentiment score of 1.63 beat Revolution Medicines' score of 1.39 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Revolution Medicines 17 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABVX or TEVA?

In the previous week, Teva Pharmaceutical Industries had 5 more articles in the media than Abivax. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 9 mentions for Abivax. Abivax's average media sentiment score of 1.63 beat Teva Pharmaceutical Industries' score of 1.26 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Teva Pharmaceutical Industries 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ABVX or ONC?

BeOne Medicines has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A BeOne Medicines $5.74B 6.23 $286.93M $4.47 72.91

Is ABVX or ONC more profitable?

BeOne Medicines has a net margin of 8.94% compared to Abivax's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% BeOne Medicines 8.94% 12.06% 6.69%

Does the media favor ABVX or ONC?

In the previous week, BeOne Medicines had 8 more articles in the media than Abivax. MarketBeat recorded 17 mentions for BeOne Medicines and 9 mentions for Abivax. Abivax's average media sentiment score of 1.63 beat BeOne Medicines' score of 0.75 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BeOne Medicines 8 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABVX or MRNA more profitable?

Abivax has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Moderna -143.55% -26.64% -19.32%

Does the media refer more to ABVX or MRNA?

In the previous week, Moderna had 5 more articles in the media than Abivax. MarketBeat recorded 14 mentions for Moderna and 9 mentions for Abivax. Abivax's average media sentiment score of 1.63 beat Moderna's score of 0.42 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Moderna 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ABVX or ROIV?

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Roivant Sciences $8.26M 3,048.63 -$299.77M -$0.60 N/A

Is ABVX or ROIV more profitable?

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Roivant Sciences -3,629.19% -20.54% -19.43%

Does the media favor ABVX or ROIV?

In the previous week, Roivant Sciences had 5 more articles in the media than Abivax. MarketBeat recorded 14 mentions for Roivant Sciences and 9 mentions for Abivax. Abivax's average media sentiment score of 1.63 beat Roivant Sciences' score of 1.34 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Roivant Sciences 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Abivax (ABVX) Competitors

$125.70 -5.46 (-4.16%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$126.38 +0.67 (+0.54%)

As of 07/24/2026 07:17 PM Eastern

Compare

ABVX vs. RVMD, TEVA, ONC, MRNA, and ROIV

Should you buy Abivax stock or one of its competitors? MarketBeat compares Abivax with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abivax include Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Moderna (MRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Abivax compare to Revolution Medicines?

Abivax (NASDAQ:ABVX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Revolution Medicines is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A

Revolution Medicines' return on equity of -83.22% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Revolution Medicines	N/A	-83.22%	-59.06%

47.9% of Abivax shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Abivax presently has a consensus target price of $156.50, suggesting a potential upside of 24.50%. Revolution Medicines has a consensus target price of $144.67, suggesting a potential downside of 23.55%. Given Abivax's higher possible upside, equities research analysts plainly believe Abivax is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Abivax has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, Revolution Medicines had 14 more articles in the media than Abivax. MarketBeat recorded 23 mentions for Revolution Medicines and 9 mentions for Abivax. Abivax's average media sentiment score of 1.63 beat Revolution Medicines' score of 1.39 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Revolution Medicines	17 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Abivax on 9 of the 14 factors compared between the two stocks.

How does Abivax compare to Teva Pharmaceutical Industries?

Abivax (NASDAQ:ABVX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

47.9% of Abivax shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Abivax's net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Abivax presently has a consensus target price of $156.50, suggesting a potential upside of 24.50%. Teva Pharmaceutical Industries has a consensus target price of $41.78, suggesting a potential upside of 35.71%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Teva Pharmaceutical Industries has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Teva Pharmaceutical Industries	$17.26B	2.05	$1.41B	$1.33	23.15

Abivax has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 5 more articles in the media than Abivax. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 9 mentions for Abivax. Abivax's average media sentiment score of 1.63 beat Teva Pharmaceutical Industries' score of 1.26 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Teva Pharmaceutical Industries	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Teva Pharmaceutical Industries beats Abivax on 11 of the 14 factors compared between the two stocks.

How does Abivax compare to BeOne Medicines?

Abivax (NASDAQ:ABVX) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Abivax has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, BeOne Medicines had 8 more articles in the media than Abivax. MarketBeat recorded 17 mentions for BeOne Medicines and 9 mentions for Abivax. Abivax's average media sentiment score of 1.63 beat BeOne Medicines' score of 0.75 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BeOne Medicines	8 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
BeOne Medicines	$5.74B	6.23	$286.93M	$4.47	72.91

Abivax currently has a consensus price target of $156.50, suggesting a potential upside of 24.50%. BeOne Medicines has a consensus price target of $394.00, suggesting a potential upside of 20.90%. Given Abivax's higher probable upside, analysts clearly believe Abivax is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

BeOne Medicines has a net margin of 8.94% compared to Abivax's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
BeOne Medicines	8.94%	12.06%	6.69%

Summary

BeOne Medicines beats Abivax on 11 of the 15 factors compared between the two stocks.

How does Abivax compare to Moderna?

Abivax (NASDAQ:ABVX) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, Moderna had 5 more articles in the media than Abivax. MarketBeat recorded 14 mentions for Moderna and 9 mentions for Abivax. Abivax's average media sentiment score of 1.63 beat Moderna's score of 0.42 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Moderna	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Abivax presently has a consensus price target of $156.50, indicating a potential upside of 24.50%. Moderna has a consensus price target of $40.00, indicating a potential downside of 26.02%. Given Abivax's stronger consensus rating and higher probable upside, research analysts plainly believe Abivax is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82

Abivax has higher earnings, but lower revenue than Moderna. Abivax is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Moderna	$2.20B	9.73	-$2.82B	-$8.15	N/A

Abivax has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Abivax has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Moderna	-143.55%	-26.64%	-19.32%

Summary

Moderna beats Abivax on 8 of the 15 factors compared between the two stocks.

How does Abivax compare to Roivant Sciences?

Abivax (NASDAQ:ABVX) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Abivax currently has a consensus price target of $156.50, suggesting a potential upside of 24.50%. Roivant Sciences has a consensus price target of $33.59, suggesting a potential downside of 4.05%. Given Abivax's stronger consensus rating and higher possible upside, research analysts clearly believe Abivax is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Roivant Sciences had 5 more articles in the media than Abivax. MarketBeat recorded 14 mentions for Roivant Sciences and 9 mentions for Abivax. Abivax's average media sentiment score of 1.63 beat Roivant Sciences' score of 1.34 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Roivant Sciences	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Roivant Sciences	$8.26M	3,048.63	-$299.77M	-$0.60	N/A

Abivax has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Roivant Sciences beats Abivax on 9 of the 15 factors compared between the two stocks.

Get Abivax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVX vs. The Competition

Export

Metric	Abivax	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.43B	$3.67B	$6.88B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-24.13	21.11	27.00	23.71
Price / Sales	N/A	166.46	491.80	74.83
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	19.13	7.88	10.28	6.07
Net Income	-$380.27M	$23.81M	$3.60B	$331.84M
7 Day Performance	-8.01%	-3.79%	-1.25%	-1.53%
1 Month Performance	36.08%	-2.59%	-0.35%	-2.46%
1 Year Performance	89.05%	32.85%	18.41%	13.66%

Abivax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVX Abivax	4.0146 of 5 stars	$125.70 -4.2%	$156.50 +24.5%	+80.2%	$11.43B	N/A	N/A	61	Positive News Analyst Forecast
RVMD Revolution Medicines	1.8298 of 5 stars	$186.39 +1.3%	$144.00 -22.7%	+408.4%	$39.39B	$11.58M	N/A	250	News Coverage Positive News Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.7178 of 5 stars	$31.88 -0.9%	$41.78 +31.1%	+88.2%	$36.91B	$17.26B	24.13	33,950	Positive News Upcoming Earnings
ONC BeOne Medicines	4.2689 of 5 stars	$304.71 +0.2%	$391.38 +28.4%	+9.9%	$33.52B	$5.34B	68.35	12,000	Trending News Analyst Forecast
MRNA Moderna	1.5835 of 5 stars	$67.16 +0.2%	$38.27 -43.0%	+59.0%	$26.49B	$1.94B	N/A	4,700	Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abivax (ABVX) Competitors

ABVX vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Abivax compare to Revolution Medicines?

Summary

How does Abivax compare to Teva Pharmaceutical Industries?

Summary

How does Abivax compare to BeOne Medicines?

Summary

How does Abivax compare to Moderna?

Summary

How does Abivax compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX vs. The Competition

Abivax Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abivax (ABVX) Competitors

ABVX vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Abivax compare to Revolution Medicines?

Which has preferable earnings and valuation, ABVX or RVMD?

Is ABVX or RVMD more profitable?

Do institutionals and insiders hold more shares of ABVX or RVMD?

Do analysts rate ABVX or RVMD?

Which has more volatility & risk, ABVX or RVMD?

Does the media favor ABVX or RVMD?

Summary

How does Abivax compare to Teva Pharmaceutical Industries?

Do insiders & institutionals hold more shares of ABVX or TEVA?

Is ABVX or TEVA more profitable?

Do analysts prefer ABVX or TEVA?

Which has stronger earnings and valuation, ABVX or TEVA?

Which has more volatility & risk, ABVX or TEVA?

Does the media favor ABVX or TEVA?

Summary

How does Abivax compare to BeOne Medicines?

Which has more risk & volatility, ABVX or ONC?

Do institutionals and insiders hold more shares of ABVX or ONC?

Does the media favor ABVX or ONC?

Which has preferable valuation and earnings, ABVX or ONC?

Do analysts recommend ABVX or ONC?

Is ABVX or ONC more profitable?

Summary

How does Abivax compare to Moderna?

Does the media refer more to ABVX or MRNA?

Do analysts recommend ABVX or MRNA?

Which has preferable valuation & earnings, ABVX or MRNA?

Which has more volatility & risk, ABVX or MRNA?

Do institutionals & insiders believe in ABVX or MRNA?

Is ABVX or MRNA more profitable?

Summary

How does Abivax compare to Roivant Sciences?

Is ABVX or ROIV more profitable?

Do analysts prefer ABVX or ROIV?

Does the media favor ABVX or ROIV?

Which has preferable valuation and earnings, ABVX or ROIV?

Which has more risk & volatility, ABVX or ROIV?

Do insiders and institutionals believe in ABVX or ROIV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX vs. The Competition

Abivax Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools